Uric Acid Stone Dissolution Versus Surgery for an Obstructing Ureteral Stone
A pure uric acid stone is the one kind that can genuinely dissolve with medication alone — the real question is whether an obstructing stone with mild hydronephrosis is still safe to wait on.
Priya S., a 34-year-old bakery owner, has been standing over proof boxes and ovens six days a week since she opened her shop four years ago, and the pain that finally sent her to the emergency department was sharp enough to make her sit down mid-shift for the first time anyone there can remember. Her pain is controlled now, but the stone hasn't passed, and she's already asked, twice, how much time off work any of the options in front of her would actually require.
Non-contrast CT shows an 8mm mid-ureteral stone at 340 Hounsfield units, with mild, unchanged hydronephrosis and no fever, rising white count, or other sign of infection. That density is the finding that points to composition: uric acid stones are the ones invisible on plain radiography, yet image readily on CT, and at 340 units hers sits far below the 600-to-700 a calcium oxalate stone returns. Density alone is suggestive, not diagnostic — only stone analysis or dual-energy CT settles composition — but low attenuation with acidic urine and no infection markers is the accepted non-invasive basis for treating a stone as uric acid. Her 24-hour urine confirms the mechanism: a persistently acidic pH of 5.2, the specific abnormality that drives uric acid, which is far more soluble in alkaline urine, to precipitate into stones in the first place. Her gout, diagnosed two years ago and controlled with diet alone since, is likely part of the same underlying picture rather than a separate problem — both conditions trace back to how her body handles uric acid, and the persistently acidic urine that's driving her stone risk is a separate variable from the serum uric acid level her gout is tracked by, which is why one being quiet doesn't mean the other is. That composition matters because uric acid is the one common stone type that can genuinely dissolve with medication alone rather than requiring mechanical removal — alkalinizing therapy held at a urine pH of 7.0 to 7.2 can dissolve an existing uric acid stone over several weeks, the upper bound there because pushing higher trades a uric acid stone for a calcium phosphate one. Her 8mm burden, preserved function and absent infection markers all sit inside the profile guidance describes for a dissolution attempt. The hydronephrosis is the one number that does not. European guidance treats uric acid obstruction of the collecting system as a setting for chemolysis combined with urinary drainage, not chemolysis alone — and mild and unchanged still means obstructed. The question is not whether to dissolve her stone but whether the four weeks that takes can safely be spent with her kidney backed up behind it.
At the urology-nephrology consult, before discharge
I want to separate two questions that I think are about to get run together. Whether we dissolve this stone or extract it is one question. Whether her kidney stays obstructed while we find out is a different one, and European guidance answers it: for uric acid obstruction of the collecting system, chemolysis is paired with urinary drainage, not offered instead of it. Mild and unchanged hydronephrosis is still hydronephrosis. I'd place a stent today. That is not me overruling the dissolution plan — it's me refusing to let four weeks of alkalinization double as four weeks of untreated obstruction.
That's a fair split, and I'll concede the drainage point rather than argue it — I was treating “unchanged” as though it meant “not obstructing,” and it doesn't. What I don't want lost is that uric acid is the one stone type that can genuinely dissolve with medication, and her numbers match what guidance describes for trying it: 340 Hounsfield units, urine pH 5.2, preserved function, no infection. A stent plus alkalinization still gets her out of definitive ureteroscopy and back on her feet at the bakery faster than a laser and a basket would. So: decompress, yes. Extract, not yet.
One clarification on the drug side, since this comes up often: allopurinol doesn't dissolve the stone that's already there — it lowers future uric acid production, which matters for preventing the next one, but the alkalinizing agent, potassium citrate, is what actually does the dissolving. There's a third lever neither of you has named. An alpha-blocker doesn't dissolve or prevent anything; it relaxes distal ureteral smooth muscle to help a stone pass, and alkalinization combined with tamsulosin has randomized support for improving passage of ureteral uric acid stones above 5mm. Hers is 8mm. Three drugs, three different questions — and I'd want her told which one is doing what, because if she stops the citrate because “the allopurinol is for the stone,” the dissolution stops with it. One target to hold her to: pH 7.0 to 7.2 on her strips, not higher, or we trade her uric acid stone for a calcium phosphate one.
Agreed: place a ureteral stent to relieve the obstruction today, then trial potassium citrate with tamsulosin and adjunctive allopurinol, with home pH monitoring held to 7.0–7.2, and repeat imaging at four weeks to check for size reduction — with explicit, named red-flag criteria (fever, worsening pain, worsening hydronephrosis despite the stent) that trigger definitive ureteroscopy regardless of the four-week timeline.
Continue alkalinization and allopurinol, with repeat imaging to confirm continued dissolution.
Proceed directly to definitive ureteroscopy — the urologist and nephrologist set this threshold together in advance, rather than deciding case-by-case under pressure later. Not agreed: how long a stented patient can reasonably be left on a dissolution trial, given that decompression removes the very urgency the four-week limit was protecting against. The urologist wanted the limit held at four weeks for exactly that reason.